ProCE Banner Activity

FINCH 1: Phase III Trial of Filgotinib in Patients With Rheumatoid Arthritis With Inadequate Response to Methotrexate

Slideset Download
Conference Coverage
Add-on therapy with JAK1 inhibitor filgotinib demonstrated improved responses compared with placebo in patients with RA who had inadequate response to methotrexate.

Released: June 18, 2019

Expiration: June 16, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead

Lilly

Sanofi Genzyme and Regeneron Pharmaceuticals